Skip to main
ELV

ELV Stock Forecast & Price Target

ELV Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 33%
Hold 28%
Sell 0%
Strong Sell 0%

Bulls say

Elevance Health is expected to continue its strong growth across its business lines, benefiting from its scale and unique position as the largest single provider of Blue Cross Blue Shield branded coverage. The company's solid financials and portfolio diversification make it an attractive investment, with potential for continued margin expansion and upside potential from its commercial and Medicare Advantage businesses. However, risks include potential volatility in the ACA market and Medicaid cost utilization spikes.

Bears say

Elevance Health is expected to face increased pressure in the commercial market and could be negatively impacted by adverse regulatory or legislative changes. The company also faces challenges in controlling medical costs, growing their government pay business, and expanding their third-party PBM business. Additionally, there are risks associated with potential deterioration in the risk pool in the ACA market, cost utilization spikes in Medicaid, and lack of growth in Carelon uptake. However, despite these challenges, Elevance Health's strong position as the largest Blue Cross Blue Shield provider and strategic acquisitions in the government-sponsored programs could lead to margin expansion opportunities in the future.

ELV has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 33% recommend Buy, 28% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elevance Health Inc (ELV) Forecast

Analysts have given ELV a Buy based on their latest research and market trends.

According to 18 analysts, ELV has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $408.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $408.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elevance Health Inc (ELV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.